What is GeneDx Holdings's debt repayments?

GeneDx Holdings (WGS) reported debt repayments of $2M in Q1 2023.

What does debt repayments mean?

Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.

GeneDx Holdings WGS Debt Repayments

Debt Repayments at other companies

Bio-Rad LaboratoriesBIO

$100K0.0%

Quest DiagnosticsDGX

$1M-99.8%

RevvityRVTY

$0+100%

Labcorp HoldingsLH

$0-100%

Agilent TechnologiesA

$1M—

DanaherDHR

$1.43B—

Other financials

Income statement

See full

Revenue$102.3M+17.4%

Gross profit$68.2M+16.6%

Operating income-$57.5M-1,163%

Net income-$63.3M-870%

EPS (diluted)-$2.16-839%

Balance sheet

See full

Cash & equivalents$94.9M-5.7%

Total debt$96.7M+82.5%

Total equity$254.1M-1.3%

Total assets$506.3M+13.4%

Cash flow

See full

Operating cash flow-$32.4M-418%

CapEx$6.5M+5.3%

Free cash flow-$38.9M-1,059%

Valuation

See full

Market cap$1.89B-24.3%

Profitability

See full

Gross margin69.6%+4.3pp

Operating margin-14.9%—

Net margin-17.6%—

FCF margin3.8%+2.1pp

Returns & leverage

See full

Return on equity-30.4%—

Debt / equity0.4×+0.2×

Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.

The official record: GeneDx Holdings’s 10-Q, filed May 9, 2023, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's debt repayments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is GeneDx Holdings's debt repayments?: GeneDx Holdings (WGS) reported debt repayments of $2M in Q1 2023.
What does debt repayments mean?: Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.